Though interest in robotics is high in Europe, much of the commercial opportunity will likely fall to two small US companies who are just now aggressively spreading the gospel of robotics through affiliations with minimally-invasive surgery pioneers. That's not to say that European companies are standing idly by: Germany's Maquet is pushing forward with an orthopedic robot. Many obstacles to adoption remain for robots, but the high cost of these units may not be as much of a problem as might be expected. The goal--and challenge--for robotic companies and their clinical advocates: to firmly establish computer-assisted surgery as an important new platform and clinical advance in surgical practice.
by David Cassak
Part II of a two part-series
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.
Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.
Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.
S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.
An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.
Flagship Pioneering senior partner Raj Panjabi discusses shifting health care from reactive treatment to AI-powered prediction and prevention of disease before symptoms emerge.
Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.
